Beijing Luzhu Biotechnology Co., Ltd.

Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in Mainland China. Its clinical-stage product candidates include LZ901, a recombinant herpes zoster vaccine, which completed Phase III clinical trial; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection product for the treatment of various autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis, that completed Phase I clinical trial; and K193, a bispecific antibody injection to treat B cell leukemia and lymphoma, which is in Phase I clinical trial. The company’s pre-clinical-stage product candidates comprise Recombinant Varicella vaccine for the prevention of varicella in children; Recombinant Syncytial Virus (RSV) vaccine for the indication of RSV-induced lower respiratory tract disease; Recombinant HSV-1 vaccine that targets oral herpes or cold sores; Recombinant HSV-2 vaccine targets genital herpes; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932 bispecific antibody to treat b cell lymphoma. In addition, it offers immunoreagents, such as Group A meningococcal polysaccharide IgG, Group C meningococcal polysaccharide IgG, Group Y meningococcal polysaccharide IgG, Group W135 meningococcal polysaccharide IgG, and Haemophilus influenzae Type B polysaccharide IgG antibody detection kits. The company was formerly known as Beijing Luzhu Biotech. The company was incorporated in 2001 and is headquartered in Beijing, China.